OFM
BCAX

Omega Fund Management’s Bicara Therapeutics BCAX Stock Holding History

Omega Fund Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1M Sell
1,822,150
-570,000
-24% -$12.7M 29.14% 1
2026
Q1 		$47.6M Buy
2,392,150
+187,500
+9% +$3.23M 29.16% 1
2025
Q4 		$37.1M Hold
2,204,650
– – 12.95% 4
2025
Q3 		$34.8M Hold
2,204,650
– – 15.66% 4
2025
Q2 		$20.5M Hold
2,204,650
– – 13.26% 5
2025
Q1 		$28.7M Hold
2,204,650
– – 16.95% 2
2024
Q4 		$38.4M Hold
2,204,650
– – 24.91% 1
2024
Q3 		$56.2M Buy
+2,204,650
New +$56.2M 35.09% 1

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Omega Fund Management's BCAX Position: Q2 2026 in Review

Omega Fund Management reduced its Bicara Therapeutics (BCAX) stake by 24% in Q2 2026, selling an estimated $12.7M and leaving 1,822,150 shares worth $54.1M. The position accounts for 29.14% of the portfolio, ranked #1.

Omega Fund Management first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $56.2M in Q3 2024. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Omega Fund Management held 1,822,150 shares of Bicara Therapeutics worth $54.1M as of Q2 2026.
  • Omega Fund Management sold 570,000 Bicara Therapeutics shares in Q2 2026, an estimated $12.7M.
  • Bicara Therapeutics made up 29.14% of Omega Fund Management's portfolio in Q2 2026, its #1 holding.
  • Omega Fund Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Omega Fund Management's Bicara Therapeutics position peaked at $56.2M in Q3 2024.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Omega Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.